Rhythm Pharmaceuticals, Inc. (RYTM) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Rhythm Pharmaceuticals, Inc. (RYTM) closed at USD 86.71 on 2026-10-14, a change of -23.6 % over the past year, with a market capitalization of USD 6.03B.

Rhythm Pharmaceuticals, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Rhythm Pharmaceuticals, Inc. key figures

Previous close

USD 86.71 (2026-10-14)

1-year change

-23.6 %

Market cap

USD 6.03B

Enterprise value

USD 5.95B

P/E ratio (trailing)

-27.84

P/E ratio (forward)

-138.83

EPS (trailing)

-3.16

EPS (forward)

-0.63

PEG ratio

n/a

Price to book

58.80

Revenue growth

46.9 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

16.33

Employees

414

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Rhythm Pharmaceuticals, Inc. and compare it with other stocks.